SCHEMBL314169

SCHEMBL314169

CC(C)(C)OC(=O)N1CCC2(CC1)CCC(O)(c1ccc(Cl)c(Cl)c1)CC2

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 4/20 0.46
GPR119 Q8TDV5 3/20 0.44
KDM1A O60341 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
DRD2 P14416 2/20 0.41
TACR1 P25103 1/20 0.41
GPR183 P32249 1/20 0.40
SCD5 Q86SK9 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
CCR1 P32246 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL654359 0.93 CCR5 (0.47) CCR5MEN1KMT2ADRD2TACR1
SCHEMBL3118407 0.86 CCR5 (0.47) CCR5MEN1KMT2ADRD2TACR1
SCHEMBL1977954 0.82 CCR1 (0.47) GPR119MEN1KMT2ADRD2TACR1
SCHEMBL3078681 0.81 KDM4E (0.49) MEN1KMT2ADRD2
SCHEMBL2273617 0.81 OPRM1 (0.56) GPR119DRD2
SCHEMBL3984793 0.81 CCR5 (0.44) CCR5MEN1KMT2ADRD2
SCHEMBL5075026 0.81 DRD2 (0.44) MEN1KMT2ADRD2CCR1
SCHEMBL12497627 0.81 TSHR (0.47) CCR5MEN1KMT2ATACR1ALOX15
SCHEMBL13070850 0.81 OPRM1 (0.47) CCR5MEN1KMT2ATACR1ALOX15
SCHEMBL2340092 0.81 CCR1 (0.44) CCR5GPR119MEN1KMT2ATACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093388-B2 3-aza spiro[5,5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2012-01-10 US disclosed
EP-1899301-B1 NOVEL 3-AZA-SPIRO[5.5]UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-09-15 EP disclosed
US-20090036477-A1 Novel 3-Aza-Spiro[5,5]Undec-8-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors ANIONA APS (DK) 2009-02-05 US disclosed
EP-1899301-A1 NOVEL 3-AZA-SPIROÝ5.5¨UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-03-19 EP disclosed
WO-2007000464-A1 NOVEL 3-AZA-SPIRO[5.5]UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036477-A1 Novel 3-Aza-Spiro[5,5]Undec-8-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC18A3 CCR5 1122/4885GPR119 226/4885KDM1A 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.